$6.89 Billion is the total value of Bellevue Group AG's 202 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
VRNA | New | VERONA PHARMA PLCsponsored ads | $5,274,675 | – | 262,683 | +100.0% | 0.08% | – |
BBIO | New | BRIDGEBIO PHARMA INC | $1,369,508 | – | 82,600 | +100.0% | 0.02% | – |
ETNB | New | 89BIO INC | $1,020,410 | – | 67,000 | +100.0% | 0.02% | – |
New | VENTYX BIOSCIENCES INC | $854,250 | – | 25,500 | +100.0% | 0.01% | – | |
ZTS | New | ZOETIS INCcl a | $228,522 | – | 1,373 | +100.0% | 0.00% | – |
DGX | New | QUEST DIAGNOSTICS INC | $123,088 | – | 870 | +100.0% | 0.00% | – |
HSIC | New | HENRY SCHEIN INC | $85,046 | – | 1,043 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- BB Biotech AG #1
- Bellevue Asset Management AG #2
- Bellevue Asset Management (UK) Ltd. #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
Incyte Corporation | 31 | Q3 2023 | 5.4% |
INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
ABBOTT LABS | 31 | Q3 2023 | 4.6% |
ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
SC 13G | 2023-02-14 |
SC 13G | 2023-02-14 |
13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.